A cost-effectiveness analysis of treatment of diabetic complications in 2002

Abstract

INTRODUCTION. For the time being no complex elaboration on the topic have been carried out in Poland thus results of the study could make it easier to emphasize the role of proper prophylaxis on reduction of incidence of diabetic complications and costs of diabetes in Poland in perspective of public payer; it could occur basic for new diabetes policy in Poland.
MATERIAL AND METHODS. The aim of the study was to assess costs for treatment of diabetes complications as well as an elaboration of a group of complications: microangiopathy or macroangiopathy are more cost-generating for public payer in 2002. Relevant data was obtained from two sources: identification of patients with diagnosed diabetes; identification of all procedures for treatment of the patients.
RESULTS. Costs for reimbursement for treatment of diabetes complications in Poland in 2002 were assessed to be 435 million PLN in 2002.
CONCLUSIONS. Proper prophylaxis and reduction of incidence of diabetic complications would mean lower costs for treatment of diabetic complications. Pharmacoeconomic elaboration should occur a new impulse for new diabetic policy which mean elaboration and implementation for more efficient health programmes and better control for glucose level in diabetic patients in Poland.